The Hospital for Sick Children
Toronto, Canada
Dr. Uri Tabori’s research focuses on the development of systems for early detection, intervention and therapeutics in individuals highly predisposed to developing cancer.
Dr. Tabori leads the international Replication Repair Deficiency (RRD) consortium at SickKids, which supports patients and families through diagnosis, management and introduction of novel therapies in 45 countries around the world. The consortium is running international clinical trials for children with hypermutant cancers with immune checkpoint inhibitors and combinations with other immune and targeted therapies. Dr. Tabori is also developing animal models and investigating companion biomarkers designed for immunotherapy therapeutics.
Dr. Tabori co-leads the pediatric low grade glioma taskforce, which uncovers novel alterations in this common childhood brain tumor and offers targeted therapies and trials. He is responsible for the development of companion biomarkers in these trials.
